New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
08:41 EDTIMMUImmunomedics reports epratuzumab effects on B-Cell in preclinical study
Immunomedics reported that its lead antibody drug candidate, epratuzumab, has a distinct way of reducing the immune response of B cells, which, in an autoimmune disease such as lupus, are responsible for producing antibodies that attack the patient's own body. Epratuzumab is a humanized antibody targeting the CD22 receptor on B cells. Epratuzumab is being developed in SLE by UCB who hold the worldwide development rights for this compound in autoimmune diseases. Importantly, PBMCs treated with epratuzumab at concentrations ranging from 1 ng/mL to 10 mg/mL produced a U-shaped curve of CD22 with substantial dampening at concentrations lower than 10 ng/mL or greater than 1 mg/mL. These observations may explain why epratuzumab was found in a number of lymphoma and SLE clinical trials to be effective at the mid-doses given and less so at the lower or higher doses. A similar profile was observed for CD19, which was reduced to a similar level over a broad concentration range of epratuzumab.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 19, 2015
14:34 EDTIMMUImmunomedics presents updated results with sacituzumab govitecan in lung cancer
Immunomedics announced that 33% of patients with small cell lung cancer, SCLC, and 31% with non-small cell lung cancer, NSCLC, had their tumor reduced in size by 30% or more, after being treated with sacituzumab govitecan, the company's lead investigational antibody-drug conjugate, ADC. Including patients that reported stable disease as their best response, the ADC controls the progression of the cancer in 75% and 56% of NSCLC and SCLC patients, respectively. These patients had either failed to respond to their last lung cancer therapies or their cancer had returned or progressed. Dr. Francois Wilhelm, Chief Medical Officer, presented the updated results at the 15th Annual Targeted Therapies of Lung Cancer Meeting, an invitation-only meeting sponsored by The International Association for the Study of Lung Cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use